Latest Growth Strategy News

APA Group has reported robust half-year results, boosting its organic growth pipeline to nearly $3 billion and reaffirming its full-year guidance amid ongoing cost reductions and strategic divestments.

AIC Mines Limited reported robust half-year results for December 2025, boosted by higher copper and gold prices despite weather-related sales disruptions. The company’s Jericho project and Eloise plant expansion remain on track, underpinning growth prospects.

Genesis Minerals has reported a remarkable fourfold increase in net profit after tax to A$238 million for the first half of FY26, driven by a 58% rise in gold production and robust margins. The company’s strong cash position and accelerated growth plans position it well for the year ahead.

Capricorn Metals has secured the Extension Hill and Mungada tenements adjacent to its Mt Gibson Gold Project, aiming to boost exploration potential in a prolific Western Australian gold belt.

RLF AgTech has secured strategic distribution partnerships with two leading Indian agricultural groups, marking its commercial entry into one of the world’s largest crop nutrition markets. These agreements position RLF for rapid expansion in India’s vast and growing agricultural sector.

Ramelius Resources has delivered its first ore from the Never Never deposit to the Mt Magnet plant, marking a key step in its growth strategy, while also closing out its FY27 gold hedge book to increase exposure to rising gold prices.

Elevra Lithium reported solid Q2 FY26 production and revenue results while progressing its North American Lithium brownfield expansion and forging strategic supply partnerships.

Caspin Resources has announced a maiden resource estimate for its Bygoo Tin Project, highlighting significant potential to grow its high-grade tin deposits amid a rising tin market. The company is also advancing gold exploration at its Weethalle Project, signalling a diversified growth strategy.

Medibank Private Limited reported a 6% rise in operating profit for the half-year ended December 2025, despite an 11% drop in net profit after tax amid ongoing cybercrime-related costs and legal challenges. The company also raised its interim dividend by 6.4%, signalling confidence in its capital position and growth strategy.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Chrysos Corporation Limited reported a robust 1H FY26 with revenue up 49% and EBITDA soaring 152%, driven by expanding adoption of its PhotonAssay technology and strategic global deployments.

Magellan Financial Group reported a 27% drop in statutory net profit but maintained stable operating profit and increased earnings per share by 5%, supported by ongoing share buybacks. The company declared a fully franked interim dividend up 50%, reflecting confidence despite investment performance challenges.